JP7751597B2 - 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤 - Google Patents

皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤

Info

Publication number
JP7751597B2
JP7751597B2 JP2022575941A JP2022575941A JP7751597B2 JP 7751597 B2 JP7751597 B2 JP 7751597B2 JP 2022575941 A JP2022575941 A JP 2022575941A JP 2022575941 A JP2022575941 A JP 2022575941A JP 7751597 B2 JP7751597 B2 JP 7751597B2
Authority
JP
Japan
Prior art keywords
compound
prednisolone
hydroxychloroquine
tlr7
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022575941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530264A5 (https=
JP2023530264A (ja
Inventor
エル シーベン，ゲイリー
ドゥドガオンカル，シャイレシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023530264A publication Critical patent/JP2023530264A/ja
Publication of JP2023530264A5 publication Critical patent/JP2023530264A5/ja
Priority to JP2025159926A priority Critical patent/JP2025183420A/ja
Application granted granted Critical
Publication of JP7751597B2 publication Critical patent/JP7751597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022575941A 2020-06-11 2021-06-10 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤 Active JP7751597B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025159926A JP2025183420A (ja) 2020-06-11 2025-09-26 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202011024586 2020-06-11
IN202011024586 2020-06-11
PCT/US2021/036740 WO2021252718A1 (en) 2020-06-11 2021-06-10 Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025159926A Division JP2025183420A (ja) 2020-06-11 2025-09-26 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤

Publications (3)

Publication Number Publication Date
JP2023530264A JP2023530264A (ja) 2023-07-14
JP2023530264A5 JP2023530264A5 (https=) 2024-04-30
JP7751597B2 true JP7751597B2 (ja) 2025-10-08

Family

ID=76959055

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022575941A Active JP7751597B2 (ja) 2020-06-11 2021-06-10 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤
JP2025159926A Pending JP2025183420A (ja) 2020-06-11 2025-09-26 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025159926A Pending JP2025183420A (ja) 2020-06-11 2025-09-26 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤

Country Status (11)

Country Link
US (1) US20230310408A1 (https=)
EP (1) EP4164639A1 (https=)
JP (2) JP7751597B2 (https=)
KR (1) KR20230023717A (https=)
CN (1) CN115701995A (https=)
AU (1) AU2021286582A1 (https=)
BR (1) BR112022024999A2 (https=)
CA (1) CA3181964A1 (https=)
IL (1) IL298667A (https=)
MX (1) MX2022015760A (https=)
WO (1) WO2021252718A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
AU2024356361A1 (en) * 2023-10-02 2026-04-02 Bristol-Myers Squibb Company A method of treating lupus
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127938A1 (en) 2005-05-24 2006-11-30 Celgene Corporation Methods and compositions using 4[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperridin-3yl) isoindole-1,3-dione for the treatment of prevention of cutaneous lupus
US20180000790A1 (en) 2016-06-29 2018-01-04 Bristol-Myers Squibb Company [1,2,4]TRIAZOLO[1,5-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582398B1 (en) * 2010-06-16 2016-04-13 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
AU2013203815A1 (en) * 2010-06-16 2013-05-02 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
WO2015200094A1 (en) * 2014-06-20 2015-12-30 Baylor Research Institute Methods and compositions for systemic lupus erythematosus (sle) therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127938A1 (en) 2005-05-24 2006-11-30 Celgene Corporation Methods and compositions using 4[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperridin-3yl) isoindole-1,3-dione for the treatment of prevention of cutaneous lupus
US20180000790A1 (en) 2016-06-29 2018-01-04 Bristol-Myers Squibb Company [1,2,4]TRIAZOLO[1,5-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS
WO2018005586A1 (en) 2016-06-29 2018-01-04 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Also Published As

Publication number Publication date
US20230310408A1 (en) 2023-10-05
BR112022024999A2 (pt) 2022-12-27
KR20230023717A (ko) 2023-02-17
WO2021252718A1 (en) 2021-12-16
EP4164639A1 (en) 2023-04-19
AU2021286582A1 (en) 2023-02-09
MX2022015760A (es) 2023-01-19
JP2025183420A (ja) 2025-12-16
CN115701995A (zh) 2023-02-14
JP2023530264A (ja) 2023-07-14
CA3181964A1 (en) 2021-12-16
IL298667A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
JP7751597B2 (ja) 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤
JP7805788B2 (ja) Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
US20220133704A1 (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
CN106163557A (zh) 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
ES2698396T3 (es) Métodos para tratar los brotes de gota
CN112807427A (zh) 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途
JPWO2019160057A1 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
JP2022533368A (ja) Ｍｋ２媒介性障害の治療方法
McDermott Rilonacept in the treatment of chronic inflammatory disorders
US20060083714A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
KR20240055038A (ko) 다발성 경화증 치료를 위한 lou064
WO2022075476A1 (en) Method for treating ox40 related disease
CN115768479A (zh) 治疗类风湿性关节炎
CA2596144A1 (en) Compounds for treating inflammatory and demyelinating diseases
EP3802600A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
WO2009019473A1 (en) Treatments for inflammatory arthritis
EA048070B1 (ru) Способы лечения кожной красной волчанки
CN111249277A (zh) 羧胺三唑类化合物在制备治疗或预防自身炎症性疾病的药物中的应用
CN118019540A (zh) 用于治疗多发性硬化的lou064
EP4652199A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
Ward et al. Antibodies in Phase III Studies for Immunological Disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240417

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250926

R150 Certificate of patent or registration of utility model

Ref document number: 7751597

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150